Why I bought Intuitive Surgical (ISRG)

Intuitive Surgical

Excerpt:

The idea of surgical robotics was little more than a curiosity until 1999, the year Intuitive Surgical introduced the da Vinci® Surgical System. Today, Intuitive Surgical is the global leader in the rapidly emerging field of robotic-assisted minimally invasive surgery. 

Comment: I'm not exactly "all in" as I only bought 1 share! Not my normal type to stock to buy .... almost exclusively purchase dividend stocks. On March 2nd, two surgeons will use a da Vinci robot to remove my prostate. Some cool videos below:





More on the stock:

Intuitive Surgical (ISRG) is a Zacks Rank #1(Strong Buy) that designs, manufacturers and markets the da Vinci surgical systems and related instruments. The da Vinci surgical system, which operates in hospitals worldwide, is the primary driver for growth. The system can be best described as a robotic surgeon, controlled by a human operator, which enhances visualization and precision for that operator. Benefits for the patients include less pain, less blood loss, shorter hospital stay and quicker recover. Intuitive Surgical has a market cap of $21 Billion with a Forward PE of 32. The company has Zacks Style Score in Momentum of “A” and is sitting only a couple percentage points away from its 52-week highs. Last week’s earnings were impressive, causing the stock to head almost 5% higher before pulling back. The company reported Q4 revenue at $5.89 vs $5.01 expected, with revenue coming in at $677 Million vs the $617 Million expected. Da Vinci systems revenue was up 8% year over year, while service revenue was up 9% over the same period. Worldwide da Vinci procedures were up 15% year over year, showing the popularity and momentum of robotic surgery. EPS surprises are nothing new for the company, surprising to the upside six out of the last seven quarters. Estimates are also heading higher, with analyst revising numbers higher for 2016 and 2017. Intuitive has been a very volatile stock that has had issues in the past. One of these issues has been reoccurring lawsuits, which accused the surgical system to be flawed and cause health complications. Lawsuits are troublesome and risks to the stock, but investors are shrugging them off for now as the stock approaches all time highs.